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ABSTRACT 
Background and aim: The single nucleotide polymorphism (SNP) rs738409 in patatin-like 
phospholipase domain-containing protein 3 (PNPLA3) is associated with hepatic fat 
accumulation and disease progression in patients with non-alcoholic fatty liver disease and 
alcoholic liver disease (ALD). This study was conducted to determine whether PNPLA3 
rs738409 SNPs affect development and prognosis of hepatocellular carcinoma (HCC) in 
patients with various liver diseases. Methods: We enrolled 638 consecutive Japanese 
patients newly diagnosed with HCC between 2001 and 2010: 72 patients with hepatitis B 
virus (HBV), 462 with hepatitis C virus (HCV), and 104 with non-B non-C (NBNC). Results: 
NBNC patients exhibited large tumors of advanced TNM stages at HCC diagnosis, and had 
significantly poorer prognosis than HBV or HCV patients (P < 0.001 and <0.001, 
respectively; log-rank test). The G/G genotype of PNPLA3 rs738409 SNP had significantly 
higher distribution in NBNC patients (P < 0.001) and was significantly associated with higher 
body mass index (BMI) and an increased aspartate aminotransferase to platelet ratio index. 
No significant differences were observed in survival with differences in PNPLA3 SNP 
genotypes among the patients, although ALD patients with the G/G genotype of PNPLA3 
SNP and low BMI had significantly poorer survival than those with high BMI (P = 0.028). 
Conclusions: The G/G genotype of PNPLA3 rs738409 SNP was more frequently 
distributed, and associated with BMI and fibrosis among NBNC-HCC patients while not 
among HBV or HCV patients. These genotypes might affect on HCC prognosis in ALD 
patients, but not in HBV, HCV, or NAFLD patients.  
 
List of abbreviations:  
HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HBV, hepatitis B virus; NBNC, 
non-B non-C; NAFLD, non-alcoholic fatty liver disease; PNPLA3, patatin-like phospholipase 
domain-containing protein 3; SNP, single nucleotide polymorphism; AFP, alpha-fetoprotein; 
DCP, des-gamma-carboxy prothrombin; BMI, body mass index; APRI, aspartate 
aminotransferase to platelet ratio index; ALD, alcoholic liver disease  
INTRODUCTION 
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most 
common cause of cancer-related deaths worldwide (1-3). Various factors, including chronic 
viral infection, age, sex, alcoholic liver disease (ALD), and diabetes mellitus, are involved in 
HCC development and progression. Hepatitis C virus (HCV) and/or hepatitis B virus (HBV) 
infections are the major cause of HCC development in Japan (4-6). Recently, the incidence 
of HCC without HBV or HCV infection has increased, accounting for 12–16% of HCC 
patients in Japan (7, 8). Obesity is the leading cause of non-alcoholic fatty liver disease 
(NAFLD) (9) and represents the second major cause of cancer development in western 
countries and Japan (10, 11). Almost 25% of all HCC cases in western countries, and 8 to 
15% in Japan are estimated to originate from NAFLD (12, 13). Because the presence of 
effective predictive biomarkers for non-B non-C (NBNC) HCC development in NAFLD 
patients have not been clarified, NBNC-HCC is often diagnosed in advanced stages with 
poor prognosis (14).  
There is compelling evidence that host genetic polymorphisms are involved in HCC 
pathogenesis and may be useful as predictive biomarkers (15). The associations of 
functional genetic polymorphisms of interleukin 6 and tumor necrosis factor alpha with HCC 
development have been reported (16, 17). In the present study, we focused on the 
association of patatin-like phospholipase domain-containing protein 3 (PNPLA3) genetic 
polymorphisms with HCC prognosis. PNPLA3, also called as adiponutrin, is a member of 
the patatin-like phospholipase family and its activity is regulated by the same hormonal 
pathways that regulate fat deposition in the liver (18-20). Non-synonymous single nucleotide 
polymorphism (SNP) rs738409 C>G transversion (Ile148Met) in exon 3 of the gene 
encoding for PNPLA3 has been reported to be associated with NAFLD development (21). 
Moreover, the PNPLA3 rs738409 SNP is related to the degree of fibrosis observed in ALD 
and NAFLD (22-24); however, it is not clear whether this polymorphism affects HCC 
development and prognosis in NAFLD and ALD. The present study was conducted to 
determine whether rs738409 C>G non-synonymous PNPLA3 SNP is associated with HCC 
development and prognosis in HBV, HCV, or NBNC patients.  
 
METHODS 
Patients 
The present study enrolled 638 consecutive Japanese patients newly diagnosed with HCC 
at the Okayama University Hospital between 2001 and 2010. Liver disease etiologies were 
as follows: 462 patients with HCV-related disease, 72 with HBV-related disease, and 104 
with non-B non-C (NBNC) disease. NBNC etiologies included metabolic disorders such as 
NAFLD in 57 patients, ALD in 34 patients, and autoimmune liver diseases and cryptogenic 
liver injury in 13 patients. Heavy drinking behavior was defined as daily alcohol intake of ≥70 
grams for ALD patients, and non-drinking behavior was defined as daily alcohol intake of 
<20 grams for NAFLD patients. Fifty NAFLD patients without HCC were also included in the 
study. The study was conducted in accordance with the Helsinki Declaration, and all 
protocols were approved by the ethics committees of the institutes. All patients provided 
informed consent before study enrollment. 
 
HCC diagnosis and follow-up 
In accordance with the clinical practice manual from the Japan Society of Hepatology (25, 
26), HCC diagnosis was accomplished using imaging techniques, including ultrasonography, 
computed tomography, magnetic resonance imaging, hepatic angiography, and/or tumor 
biopsy, in combination with the detection of serum levels of alpha-fetoprotein (AFP), AFP-L3, 
and des-gamma-carboxy prothrombin (DCP). HCC staging conformed to the standards of 
general rules for clinical and pathological study of primary liver cancer by the liver cancer 
study group of Japan (27). The cancer was treated following suitable measures according to 
the treatment algorithm for HCC in the clinical practice manual from the Japan Society of 
Hepatology (18, 19). After curative treatment of primary HCC, all patients underwent liver 
function tests every 1–3 months and ultrasonography or dynamic study every 3–4 months. 
Serum levels of AFP, AFP-L3, and DCP were also determined every 1–3 months. HCC 
recurrence was diagnosed using the same criteria as those used for primary HCC diagnosis. 
HCC recurrence was treated following suitable measures.  
 
SNP genotyping 
Genomic DNA was extracted from whole blood samples using the QIAamp DNA Mini Kit 
according to the manufacturer’s protocol (Qiagen, Tokyo, Japan). PNPLA3 SNP was 
genotyped using the TaqMan predesigned SNP genotyping assays, as recommended by 
the manufacturer (Applied Biosystems, Tokyo, Japan).  
 
Statistical analysis 
Data are expressed as mean ± standard deviation or median (range). Patient laboratory 
data were compared among the groups using the Kruskal–Wallis test. Survival rates of 
patients were estimated using the Kaplan–Meier method and compared with the log-rank 
test. P < 0.05 was considered significant. Statistical analysis was performed using JMP 
software (SAS Institute, Cary, NC, USA).  
RESULTS 
Patient characteristic at diagnosis 
HCC development occurred at a much younger age in HBV patients than in HCV or NBNC 
patients (P < 0.001, Kruskal–Wallis test, Table 1). Majority of NBNC and HBV patients were 
male (P < 0.001). Body mass index (BMI) of NBNC patients was significantly higher than 
that of HBV or HCV patients (P = 0.001). The NBNC patients also exhibited the highest 
incidence of diabetes mellitus (38.5%). The incidence of diabetes mellitus was much lower 
among HCV (18.8%) and HBV patients (4.0%, lowest, P < 0.001). In terms of drinking 
behavior, 32.7% of NBNC patients drank heavily, while only 5.5% of HBV patients and 
11.0% of HCV patients (P < 0.001) were heavy drinkers. No significant differences were 
observed among the experimental groups regarding the ratio of patients with Child-Pugh A 
(P = 0.44). Significantly higher serum levels of aspartate aminotransferase and alanine 
aminotransferase as well as lower platelet counts were observed in HCV patients (P < 0.001, 
0.003, and <0.001, respectively). Gamma-glutamyl transpeptidase was significantly higher 
in NBNC patients than in HBV or HCV patients (P < 0.001).  
 
HCC diagnosis and prognosis 
At diagnosis, NBNC patients exhibited a higher incidence of large HCC tumors of advanced 
TNM stages as well as higher serum DCP levels than HBV or HCV patients (P < 0.001, 
Table 1). After curative treatment of primary HCC, all patients underwent periodical liver 
function and imaging tests at follow-up. The mean follow-up period was approximately 3.0 
years (range, 0.1–9.5 years). This period was defined as the time between diagnosis and 
death or the latest confirmation of survival. The accumulated observation time was 1914 
person-years. The survival rate of NBNC patients was significantly lower than that of HBV or 
HCV patients (P = 0.011, log-rank test, Figure 1), with an estimated 68.7% survival at 3 
years and 41.8% survival at 5 years. The survival of HCV, or NBNC patients was not 
dependent on TNM stage (Figure 2). The survival of HBV patients on TNM stage Ⅱ was 
significantly better than that of HCV or NBNC patients (P = 0.044).  
 
Subgroup analysis based on PNPLA3 rs738409 SNP 
The ratio of patients with the G/G genotype of PNPLA3 SNP was significantly greater 
among NBNC patients (46.2%) than among HBV or HCV patients (16.7% and 24.0%, 
respectively, P < 0.001, Table 1). Age and gender did not significantly correlate with 
PNPLA3 SNP genotype distribution among HBV, HCV, or NBNC patients. Among NBNC 
patients, patients with the G/G genotype of PNPLA3 SNP had significantly higher BMI than 
those with the C/C or C/G genotype (P < 0.001, Table 2), while no significant correlation was 
observed between HBV or HCV patients regarding BMI and PNPLA3 SNP genotypes. As for 
laboratory data, NBNC patients with the G/G genotype exhibited slight tendency of smaller 
tumors (P = 0.047), and higher aspartate aminotransferase to platelet ratio index (APRI) (P 
= 0.054) than those with C/C or C/G genotype; however, no significant differences were 
observed in the TNM stage and serum levels of AFP and DCP. We also compared patient 
survival to the distribution of the different PNPLA3 SNP genotypes (Figure 3). No significant 
correlation was observed between survival and the genotypes among HBV, HCV or NBNC 
patients. For HBV patients, the viral status including HBe antigen, HBs antigen, and HBV 
DNA at diagnosis did not differ based on the different PNPLA3 SNP genotypes. We further 
investigated ALD or NAFLD patients among NBNC patients. The ratio of patients with the 
G/G genotype of PNPLA3 SNP was significantly greater among NAFLD patients (56.1%) 
than the other groups with ALD or other etiologies (35.3% and 30.8%, respectively, P = 
0.046, Table 3). As presented in Figure 4, ALD patients with the G/G genotype of PNPLA3 
SNP who had BMI of <25 kg/m
2
 exhibited significantly lower survival rates than those who 
had BMI of 25 kg/m
2
 (P = 0.028, log-rank test). A similar association was not observed for 
ALD patients with the C/C or C/G genotype or NAFLD patients. To investigate the 
association of PNPLA3 SNP with carcinogenesis, the NAFLD patients with HCC were 
compared to those without HCC in the prevalence of the G/G genotype of PNPLA3 SNP. 
The genotypes of PNPLA3 SNP in the NAFLD patients without HCC were C/C in 3 patients 
(6.0%), C/G in 22 patients (44.0%), and G/G in 25 patients (50.0%), which did not have 
significant difference from those in the NAFLD patients with HCC (P = 0.61).  
DISCUSSION 
HCC is commonly associated with HBV or HCV infections; however, the incidence of 
NBNC-HCC with NAFLD or ALD has increased significantly in recent years (12, 13). The 
incidence of NBNC-HCC in the present study support the trend that non-viral associated 
HCC is increasing as the ratio of NBNC-HCC has increased from 11.8% between 2001 and 
2005 to 15.1% between 2006 and 2010. Several studies have attempted to elucidate useful 
predictors for NBNC-HCC; however, these studies were not completely successful. Recent 
genome-wide association studies revealed that PNPLA3 rs738409 SNPs are associated 
with hepatic steatosis and fibrosis (21, 28). PNPLA3 (rs738409 C>G) SNP can modulate 
hepatic inflammation and fibrosis progression (29). The G allele of PNPLA3 SNP is 
associated with increased steatosis (30-32) and severe fibrosis (22, 27, 33, 34 and 35). 
Liver cirrhosis and steatohepatitis are associated with carcinogenesis and increased 
susceptibility to HCC development; however, no published studies have focused on the role 
of PNPLA3 SNP genotypes in HCC development and prognosis. Therefore, we investigated 
PNPLA3 SNP genotypes in HCC patients to clarify the importance of this polymorphism as a 
predictor for HCC development and prognosis. 
Our results of patient characteristic at HCC diagnosis revealed that NBNC-HCC patients 
exhibited a significantly higher incidence of the G/G genotype than HCV or HBV patients 
with a higher incidence of diabetes mellitus, obesity, and alcoholic liver injury, supporting the 
results of previous studies (36-38). Furthermore, subgroup analysis revealed that the 
NBNC-HCC patients with the G/G genotype had higher BMI and APRI, reflecting obesity 
and severe fibrosis, than those with the other genotypes, and that the patients with NAFLD 
had a higher frequency of the G/G genotype than those with ALD. In contrast, among HBV 
or HCV patients with HCC, the presence of obesity or severe hepatic fibrosis showed no 
significant correlation with the PNPLA3 SNP genotypes. Therefore, these results indicated 
that among the patients with HCC, the G/G genotype of PNPLA3 SNP is strongly associated 
with NAFLD with obesity and severe fibrosis, which is a similar situation in those without 
HCC in the previous studies.  
Our results of HCC prognosis clearly showed that no significant association was observed 
between HCC prognosis and the PNPLA3 SNP genotypes in HCV or NAFLD patients. 
Interestingly, subgroup analysis of ALD patients indicated prognostic differences by the 
genotypes of PNPLA3 SNP; the ALD patients with the G/G genotype of PNPLA3 SNP and 
high BMI might maintain body weight against HCC progression and malnutrition, and 
resulted in better prognosis, by comparing to the ALD patients with low BMI, although the 
number of the ALD patients might be relatively small.   
In conclusion, our results indicate that differences in the distribution of PNPLA3 SNP 
genotypes have important and independent roles in the regulation of various liver disease 
etiologies and HCC prognosis. While the G/G genotype showed greater distribution in 
NBNC-HCC patients, only among ALD patients did the G/G genotypes but not the C/C and 
C/G genotype was associated with HCC prognosis. More research is necessary to further 
clarify the exact manner in which differences in expression of PNPLA3 SNP genotypes may 
regulate liver etiology as well as HCC development and prognosis. Longitudinal study of 
HCC development in patients without HCC is required.  
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FIGURE LEGENDS 
 
Figure 1. The patient survival rates in the three groups  
 
The patient survival rate was presumed for each group by the Kaplan–Meyer method. The 
survival of NBNC patients was significantly poorer than that of HBV or HCV patients (P = 
0.011, log-rank test), and it was estimated as 68.7% at 3 years and 41.8% at 5 years.  
 
Figure 2. The comparison of survival rates among the three groups in different TNM stages 
 
By dividing the patients based on the TNM stage at diagnosis, the patient survival rate was 
compared among the three groups of HBV, HCV, and NBNC etiology for each TNM stage. 
No prognostic differences were observed among the three groups for TNM stage Ⅰ, Ⅲ, 
or Ⅳ (P = 0.13, 0.36, and 0.64, respectively, log-rank test). The survival of HBV patients 
on TNM stage Ⅱ was significantly better than that of HCV or NBNC patients (P = 0.044). 
 
Figure 3. The comparison of survival rates based on the different PNPLA3 SNP genotypes 
in the three groups 
 
The survival rates in relation to the different PNPLA3 SNP genotypes were compared for 
the three groups of HBV, HCV, and NBNC etiology. The PNPLA3 SNP genotype was not 
significantly related to survival rates among HBV, HCV, or NBNC patients.  
 
Figure 4. The comparison of survival rates based on different BMI for NBNC patients with 
ALD or NAFLD 
 
The impact of PNPLA3 SNP on survival was evaluated by BMI for NBNC patients with ALD 
or NAFLD. Among ALD patients with the G/G genotype, patients with BMI of <25 kg/m
2
 had 
significantly poorer survival than those with BMI of 25 kg/m
2 
(P = 0.028, log-rank test). ALD 
patients with the C/C or C/G genotype of PNPLA3 or NAFLD patients showed no prognostic 
difference in BMI. 
 
Table 1: Patient characteristics  
 
 HBV 
(n = 72) 
HCV 
(n = 462) 
NBNC 
(n = 104) 
 
P 
Age (years) 61 (38–87)+ 75 (42–93)+ 71 (27–91)+ <0.0001 
Gender (female/male) 11/61 151/311 22/82 <0.0001 
Diabetes mellitus (yes) 3 87 40 <0.0001 
Heavy drinking behavior (yes) 4 51 34 <0.0001 
Body mass index 23.2  3.5
‡
 22.7  3.1
‡
 24.6  4.3
‡
 0.0001 
PNPLA rs738409 (CC/CG/GG) 20/40/12 125/226/111 17/39/48 <0.0001 
Child-Pugh score (A/B/C) 57/13/2 332/118/12 83/19/2 0.14 
APRI 4.5  3.8
‡
 7.0  7.0
‡
 4.6  4.6
‡
 <0.0001 
TNM stage (1/2/3/4) 24/24/13/11 161/155/111/35 22/32/24/26 <0.0001 
Tumor size (mm) 22  3.6
‡
 20  0.9
‡
 32  4.0
‡
 <0.0001 
Tumor number (solitary) 36 260 52 0.36 
Laboratory data     
ALT (IU/l) 40  23
‡
 57  39
‡
 46  44
‡
 0.003 
γGTP (IU/l) 103  129‡ 85  95‡ 143  146‡ <0.0001 
Albumin (g/dl) 3.9  0.6
‡
 3.6  0.5
‡
 3.7  0.5
‡
 <0.0001 
Total bilirubin (mg/dl) 1.1  0.7
‡
 1.0  0.6
‡
 1.1  0.7
‡
 0.15 
Platelet count (10
4/μl) 16.2  8.7‡ 12.4  5.9‡ 13.4  6.2‡ <0.0001 
AFP (ng/ml) 10 (0.9–67951)+ 19 (0.5–85292)+ 26 (2–455560)+ 0.54 
DCP (mAU/ml) 46 (2–410500)+ 36 (10–708400)+ 126 (11–1323600)+ <0.0001 
Anti-HBc antibody (yes)  135 35 0.44 
+
: Median (range); 
‡
: Mean  standard deviation. TNM, Tumor–node–metastasis stage 
according to the Liver Cancer Study Group of Japan; APRI, aspartate aminotransferase to 
platelet ratio index; ALT, alanine aminotransferase; γGTP, γ-glutamyl transpeptidase; AFP, 
Alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin.  
Table 2: Characteristics of NBNC patients with PNPLA3 rs738409 polymorphisms 
 
rs738409 SNP genotype C/C or C/G 
(n = 56) 
G/G 
(n = 48) 
P 
Age (years) 70 (27–91)+ 72 (46–83)+ 0.85 
Gender (female/male) 10/46 12/36 0.26 
Diabetes mellitus (yes) 20 20 0.34 
Heavy drinking behavior (yes) 22 12 0.09 
Body mass index 23.6  3.2
‡
 26.3  3.8
‡
 <0.0001 
Child-Pugh score (A/B/C) 44/8/4 39/6/3 0.46 
APRI 2.4  2.2
‡
 3.6  3.1
‡
 0.054 
TNM stage (1/2/3/4) 13/15/9/19 7/14/14/13 0.21 
Tumor size (mm) 38 (10–200) 28 (5–100) 0.047 
Laboratory data    
ALT (IU/l) 38  34
‡
 40  22
‡
 0.66 
γGTP (IU/l) 101  95‡ 85  82‡ 0.68 
Albumin (g/dl) 3.7  0.6
‡
 3.7  0.5
‡
 0.92 
Total bilirubin (mg/dl) 0.9  0.5
‡
 1.0  0.7
‡
 0.35 
Platelet count (10
4/μl) 16.1  6.9‡ 13.7  6.7‡ 0.08 
AFP (ng/ml) 8.1 (0.9–67951)+ 10.1 (2–37387)+ 0.34 
DCP (mAU/ml) 183.5 (16–472100)+ 100 (11–1323600)+ 0.33 
Anti-HBc antibody (yes) 17 18 0.29 
+
: Median (range). 
‡
: Mean  standard deviation. TNM, Tumor–node–metastasis stage 
according to the Liver Cancer Study Group of Japan; APRI, aspartate aminotransferase to 
platelet ratio index; ALT, alanine aminotransferase; γGTP, γ-glutamyl transpeptidase; AFP, 
Alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin. 
  
Table 3: Frequency of PNPLA3 rs738409 polymorphisms in NBNC patients 
 
rs738409 SNP genotype C/C 
(n = 17) 
C/G 
(n = 39) 
G/G 
(n = 48) 
NAFLD 5 (8.8%) 20 (35.1%) 32 (56.1%) 
Alcoholic liver disease 7 (20.6%) 15 (44.1%) 12 (35.3%) 
Disease for other etiologies 5 (38.4%) 4 (30.8%) 4 (30.8%) 
PNPLA3, patatin-like phospholipase domain-containing protein 3; NBNC, non-B non-C; 
SNP, single nucleotide polymorphism; NAFLD, non-alcoholic fatty liver disease.  
